Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Ascending Single Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics/Pharmacodynamics Of Pf-05280602, A Recombinant Factor Viia Variant (813d), In Adult Hemophilia A And B Subjects With Or Without Inhibitors

NCT01439971 is registered in ClinicalTrials.gov with Catalyst Biosciences as lead sponsor.

NCT NCT01439971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01439971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Ascending Single Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics/Pharmacodynamics Of Pf-05280602, A Recombinant Factor Viia Variant (813d), In Adult Hemophilia A And B Subjects With Or Without Inhibitors
Lead sponsor
Catalyst Biosciences
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2011
Completion date
October 31, 2015
Enrollment
29 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a